Ambalal Sarabhai Enterprises Ltd. BSE: 500009

Ambalal Sarabhai Enterprises Ltd. Live Share Price Today, Share Analysis and Chart

36.74 -0.16 (-0.43%)

Near 52W Low of ₹35.10

113.7K BSE Volume

BSE 13 Mar, 2025 3:31 PM (IST)

Ambalal Sarabhai Key Metrics

Select
All financials are in INR Cr and price data in INR
VIEW MORE
Loading... You have run out of DVM views! Check usage
Subscribe now to see details
High Financial Strength
70.0 / 100
Affordable Valuation
55.2 / 100
Technically Bearish
24.6 / 100
Value Stock, Under Radar These stocks are strong in quality and valuation, but score weak in technical aspects. Hence, it is better to wait for the stock to change their momentum. View Similar Embed DVM

Ambalal Sarabhai Enterprises Ltd. Live Price Chart

Fetching data ...

Ambalal Sarabhai Stock Analysis

Ambalal Sarabhai stock analysis with key metrics, changes, and trends.

Ambalal Sarabhai MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue₹183.95 Cr0.64%positive

Annual Revenue rose 0.64%, in the last year to ₹183.95 Cr. Its sector's average revenue growth for the last fiscal year was 11.87%.

Annual Net Profit₹5.68 Cr48.82%negative

Annual Net Profit fell 48.82% in the last year to ₹5.68 Cr. Its sector's average net profit growth for the last fiscal year was 26.81%.

Price to Earning Ratio19.8-positive

Price to Earning Ratio is 19.8, lower than its sector PE ratio of 38.09.

Stock Price₹36.74-20.1%negative

Stock Price fell 20.1% and underperformed its sector by 37.26% in the past year.

Quarterly Revenue₹51.58 Cr6.63%positive

Quarterly Revenue rose 6.63% YoY to ₹51.58 Cr. Its sector's average revenue growth YoY for the quarter was 9.97%.

Quarterly Net profit₹2.23 Cr89.19%positive

Quarterly Net profit rose 89.19% YoY to ₹2.23 Cr. Its sector's average net profit growth YoY for the quarter was 20.24%.

Debt to Equity Ratio0.33-positive

Debt to Equity Ratio of 0.33 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)4.14 %4.14%negative

Return on Equity(ROE) for the last financial year was 4.14%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding0.00 %0%neutral

Mutual Fund Holding remained the same in the last quarter at 0%.

Promoter Share Holding31.35 %0%neutral

Promoter Share Holding stayed the same in the most recent quarter at 31.35%.

Interest Coverage Ratio4.44-positive

Interest Coverage Ratio is 4.44, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Promoter Pledges0.00 %0%positive

Promoter Pledges are zero.

VIEW LESS


Loading data..

Earnings Conference Calls, Investor Presentations and Annual Reports

Annual Report Mar-2024
Annual Report Mar-2023
Annual Report Mar-2022
Annual Report Mar-2021
Annual Report Mar-2020
Annual Report Mar-2019
Annual Report Mar-2018
Annual Report Mar-2017
Annual Report Mar-2016
Annual Report Mar-2015
Annual Report Mar-2014
Annual Report Mar-2010

Ambalal Sarabhai Enterprises Ltd. - Company Profile

What does Ambalal Sarabhai Enterprises Ltd. do?

Ambalal Sarabhai Enterprises is engaged in manufacturing Pharmaceuticals.

Website: www.ase.life

Ambalal Sarabhai Enterprises Ltd. Management structure

All Gross Remunerations are in INR
Mr. Navinchandra R. Patel
Chief Financial Officer
27.35 Lac
2024-3-31
Gross Remuneration
Year
Disha Mahesh Punjani
Company Secretary, Compliance Officer
-
2024-3-31
Gross Remuneration
Year

Ambalal Sarabhai Enterprises Ltd. Board of directors

All Gross Remunerations are in INR
Kartikeya V Sarabhai
Executive Chairman
54.65 Lac
2024
Gross Remuneration
Year
Chaula Shastri
Whole-time Director
34.26 Lac
2024
Gross Remuneration
Year
Mayur K Swedia
Independent Director
1.7 Lac
2024
Gross Remuneration
Year
BRIJESH KHANDELWAL
Independent Director
50K
2024
Gross Remuneration
Year
Govindprasad Namdeo
Independent Director
30K
2024
Gross Remuneration
Year
Ajay Mayor
Non Executive Director
20K
2024
Gross Remuneration
Year

Ambalal Sarabhai Enterprises Ltd. - company history

Ambalal Sarabhai Enterprises Ltd., incorporated on June 5, 1978, houses a range of companies across multi-dimensional businesses. Each subsidiary is a distinct entity contributing its unique expertise and capabilities. It is one of the oldest pharmaceutical health care companies in India, and today through its group companies it manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and internationally. ASE's strength is to lead with cutting edge technology by creating strategic technology tie-ups and collaborative partnerships through our broad national and international networks The Company produces a range of bulk drugs, pharmaceutical preparations and electronic instruments. It operates in two segments, pharmaceuticals and electronics. Pharmaceuticals segment is engaged in manufacture of drugs and formulations. Electronics segment is engaged in manufacture of electronics instruments and services. In the year 1994, the company entered into a technical collaboration with Biobras, Brazil, to manufacture highly purified insulin injections. During the year 1997-98, the company formed a joint venture company, namely Sarabhai Piramal Pharmaceuticals Ltd with Piramal Enterprises Ltd for marketing of certain products under trademarks being used by the company. During the year 1998-99, the company signed agreement with B V Chiron, Netherlands for introducing their anti-cancer drugs in India. During the year 1999-2000, the company entered into an MoU for marketing of products of Oncology products of Chiron Corporation, USA. The Product Division essentially comprising of Sarabai Chemicals Products was transferred to the joint venture company, Sarabhai Piramal Pharmaceuticals Ltd. In September 2008, the company acquired the manufacturing and marketing company, namely Suvik Hitek Pvt. Ltd. The Ethical Division re-launched the products of Suvik and Sarabhai Chemicals in market. Also, the company acquired Systronics (India) Pvt Ltd. During the year 2008-09, the Oncology Division launched two new products viz. Fludagem & Xtinib. Also, the company promoted a company viz. Vovanties Laboratories Pvt Ltd, a pharmaceutical specialist with a vision to establish a state of the art manufacturing facility specializing in Novel Effervescent Drug Delivery System. During the year 2010-11, the Company had transferred and assigned as going concern, the business undertaking of Sarabhai Chemicals Bulk Drug Division to Synbiotics Ltd and Electronics Division comprising of Systronics, Teleradand SERC to Systronics (India) Ltd with effect from October 01, 2010. Sarabhai M Chemicals Ltd, a wholly owned subsidiary company started its Vitamin C coated products manufacturing since August 2019. In June 2023, Asence Pharma Pvt., Ltd. a subsidiary of the Company commenced its new oncology and synthetic API plant at Ranoli, Vadodara.

Ambalal Sarabhai Enterprises Ltd. FAQ

How is Ambalal Sarabhai Enterprises Ltd. today?
Ambalal Sarabhai Enterprises Ltd. today is trading in the red, and is down by -0.43% at 36.74.
Ambalal Sarabhai Enterprises Ltd. is currently trading down -0.43% on an intraday basis. In the past week the stock fell -5.04%. stock has been down -41.95% in the past quarter and fell -20.10% in the past year. You can view this in the overview section.